Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 7/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492660 | 0.88 | DYRK1A (0.46) | PDE3BPDE3AP2RY12PDE2AMAPT | |
| SCHEMBL526585 | 0.87 | LTA4H (0.51) | PDE3BPDE3AP2RY12DYRK1ALTA4H | |
| SCHEMBL2491624 | 0.85 | PDE4A (0.38) | PDE3BPDE3AP2RY12LMNAALDH1A1 | |
| SCHEMBL14973529 | 0.81 | LTA4H (0.39) | PDE3BPDE3AP2RY12PDE2ADYRK1A | |
| SCHEMBL526829 | 0.80 | LTA4H (0.55) | PDE3BPDE3AP2RY12MAPTLTA4H | |
| SCHEMBL525627 | 0.79 | DYRK1A (0.37) | PDE3BPDE3AP2RY12PDE2AMAPT | |
| SCHEMBL2493225 | 0.76 | SMN1; SMN2 (0.48) | PDE3BPDE3AP2RY12PDE2AMAPT | |
| SCHEMBL2490562 | 0.75 | CNR2 (0.37) | PDE3BPDE3AMAPTDYRK1ALMNA | |
| SCHEMBL21056504 | 0.73 | CCR1 (0.55) | DYRK1ALMNA | |
| SCHEMBL14973568 | 0.73 | KDM4E (0.45) | LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| EP-2170890-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2011-10-26 | — | — | EP | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-2170890-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009016516-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | TOMM34, TOMM70, TOMM40 | PDE3B 4130/4885PDE3A 4150/4885P2RY12 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.